|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zuiverloon TC, Nieuweboer AJ, Vékony H,
Kirkels WJ, Bangma CH and Zwarthoff EC: Markers predicting response
to bacillus Calmette-Guérin immunotherapy in high-risk bladder
cancer patients: A systematic review. Eur Urol. 61:128–145. 2012.
View Article : Google Scholar
|
|
3
|
Luke C, Tracey E, Stapleton A and Roder D:
Exploring contrary trends in bladder cancer incidence, mortality
and survival: Implications for research and cancer control. Intern
Med J. 40:357–362. 2010. View Article : Google Scholar
|
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lages E, Ipas H, Guttin A, Nesr H, Berger
F and Issartel JP: MicroRNAs: Molecular features and role in
cancer. Front Biosci. 17:2508–2540. 2012. View Article : Google Scholar
|
|
6
|
Xiu Y, Liu Z, Xia S, Jin C, Yin H, Zhao W
and Wu Q: Micro-RNA-137 upregulation increases bladder cancer cell
proliferation and invasion by targeting PAQR3. PLoS One.
9:e1097342014. View Article : Google Scholar
|
|
7
|
Price C and Chen J: MicroRNAs in cancer
biology and therapy: Current status and perspectives. Genes Dis.
1:53–63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tölle A, Ratert N and Jung K: miRNA panels
as biomarkers for bladder cancer. Biomarkers Med. 8:733–746. 2014.
View Article : Google Scholar
|
|
9
|
Pan X, Wang R and Wang ZX: The potential
role of miR-451 in cancer diagnosis, prognosis, and therapy. Mol
Cancer Ther. 12:1153–1162. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fukumoto I, Kinoshita T, Hanazawa T,
Kikkawa N, Chiyomaru T, Enokida H, Yamamoto N, Goto Y, Nishikawa R,
Nakagawa M, et al: Identification of tumour suppressive
microRNA-451a in hypopharyngeal squamous cell carcinoma based on
microRNA expression signature. Br J Cancer. 111:386–394. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yin P, Peng R, Peng H, Yao L, Sun Y, Wen
L, Wu T, Zhou J and Zhang Z: MiR-451 suppresses cell proliferation
and metastasis in A549 lung cancer cells. Mol Biotechnol. 57:1–11.
2015. View Article : Google Scholar
|
|
12
|
Lv G, Hu Z, Tie Y, Du J, Fu H, Gao X and
Zheng X: MicroRNA-451 regulates activating transcription factor 2
expression and inhibits liver cancer cell migration. Oncol Rep.
32:1021–1028. 2014.PubMed/NCBI
|
|
13
|
Xu H, Mei Q, Shi L, Lu J, Zhao J and Fu Q:
Tumor-suppressing effects of miR451 in human osteosarcoma. Cell
Biochem Biophys. 69:163–168. 2014. View Article : Google Scholar
|
|
14
|
Godlewski J, Nowicki MO, Bronisz A, Nuovo
G, Palatini J, De Lay M, Van Brocklyn J, Ostrowski MC, Chiocca EA
and Lawler SE: MicroRNA-451 regulates LKB1/AMPK signaling and
allows adaptation to metabolic stress in glioma cells. Mol Cell.
37:620–632. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen MB, Wei MX, Han JY, Wu XY, Li C, Wang
J, Shen W and Lu PH: MicroRNA-451 regulates AMPK/mTORC1 signaling
and fascin1 expression in HT-29 colorectal cancer. Cell Signal.
26:102–109. 2014. View Article : Google Scholar
|
|
16
|
Eble JN, Sauter G, Epstein JI and
Sesterhenn IA: World Health Organization classification of Tumours:
Pathology and Genetics of Tumours of the Urinary System and Male
Genital Organs. IARC Press; Lyon: 2004
|
|
17
|
Kawahara T, Kashiwagi E, Ide H, Li Y,
Zheng Y, Miyamoto Y, Netto GJ, Ishiguro H and Miyamoto H:
Cyclosporine A and tacrolimus inhibit bladder cancer growth through
down-regulation of NFATc1. Oncotarget. 6:1582–1593. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mehlen P and Puisieux A: Metastasis: A
question of life or death. Nat Rev Cancer. 6:449–458. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Raghavan A and Shah ZA: Withania somnifera
improves ischemic stroke outcomes by attenuating PARP1-AIF-mediated
caspase-independent apoptosis. Mol Neurobiol. 52:1093–1105. 2015.
View Article : Google Scholar
|
|
20
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer.
94:776–780. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Costa PM and Pedroso de Lima MC: MicroRNAs
as molecular targets for cancer therapy: On the modulation of
microRNA expression. Pharmaceuticals. 6:1195–1220. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu CT, Lin WY, Chang YH, Lin PY, Chen WC
and Chen MF: DNMT1-dependent suppression of microRNA424 regulates
tumor progression in human bladder cancer. Oncotarget.
6:24119–24131. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Itesako T, Seki N, Yoshino H, Chiyomaru T,
Yamasaki T, Hidaka H, Yonezawa T, Nohata N, Kinoshita T, Nakagawa
M, et al: The microRNA expression signature of bladder cancer by
deep sequencing: The functional significance of the miR-195/497
cluster. PLoS One. 9:e843112014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li X, Sanda T, Look AT, Novina CD and von
Boehmer H: Repression of tumor suppressor miR-451 is essential for
NOTCH1-induced oncogenesis in T-ALL. J Exp Med. 208:663–675. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kovalchuk O, Filkowski J, Meservy J,
Ilnytskyy Y, Tryndyak VP, Chekhun VF and Pogribny IP: Involvement
of microRNA-451 in resistance of the MCF-7 breast cancer cells to
chemotherapeutic drug doxorubicin. Mol Cancer Ther. 7:2152–2159.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zeng T, Peng L, Chao C, Fu B, Wang G, Wang
Y and Zhu X: miR-451 inhibits invasion and proliferation of bladder
cancer by regulating EMT. Int J Clin Exp Pathol. 7:7653–7662.
2014.
|
|
27
|
Hofmann UB, Houben R, Bröcker EB and
Becker JC: Role of matrix metalloproteinases in melanoma cell
invasion. Biochimie. 87:307–314. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Strand S, Vollmer P, van den Abeelen L,
Gottfried D, Alla V, Heid H, Kuball J, Theobald M, Galle PR and
Strand D: Cleavage of CD95 by matrix metalloproteinase-7 induces
apoptosis resistance in tumour cells. Oncogene. 23:3732–3736. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Abraham R, Schäfer J, Rothe M, Bange J,
Knyazev P and Ullrich A: Identification of MMP-15 as an
anti-apoptotic factor in cancer cells. J Biol Chem.
280:34123–34132. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Perron MP and Provost P: Protein
interactions and complexes in human microRNA biogenesis and
function. Front Biosci. 13:2537–2547. 2008. View Article : Google Scholar
|
|
31
|
Chen BJ, Wu YL, Tanaka Y and Zhang W:
Small molecules targeting c-Myc oncogene: Promising anti-cancer
therapeutics. Int J Biol Sci. 10:1084–1096. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dang CV: MYC on the path to cancer. Cell.
149:22–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Seo HK, Ahn KO, Jung NR, Shin JS, Park WS,
Lee KH, Lee SJ and Jeong KC: Antitumor activity of the c-Myc
inhibitor KSI-3716 in gemcitabine-resistant bladder cancer.
Oncotarget. 5:326–337. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lin F, Ding R, Zheng S, Xing D, Hong W,
Zhou Z and Shen J: Decreased expression of microRNA-744 promotes
cell proliferation by targeting c-Myc in human hepatocellular
carcinoma. Cancer Cell Int. 14:582014. View Article : Google Scholar
|
|
35
|
Liu Z, Zhang G, Li J, Liu J and Lv P: The
tumor-suppressive microRNA-135b targets c-myc in osteoscarcoma.
PLoS One. 9:e1026212014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang X, Cai H, Liang Y, Chen L, Wang X, Si
R, Qu K, Jiang Z, Ma B, Miao C, et al: Inhibition of c-Myc by
let-7b mimic reverses mutidrug resistance in gastric cancer cells.
Oncol Rep. 33:1723–1730. 2015.PubMed/NCBI
|
|
37
|
Lü M, Ding K, Zhang G, Yin M, Yao G, Tian
H, Lian J, Liu L, Liang M, Zhu T, et al: MicroRNA-320a sensitizes
tamoxifen-resistant breast cancer cells to tamoxifen by targeting
ARPP-19 and ERRγ. Sci Rep. 5:87352015. View Article : Google Scholar
|
